Big biotech, Insight journal - Dealtalk

The top 15 big biotech venture investments in H1 2012

Posted on 02 August 2012

Tags: ,

Perhaps it's no surprise that much of the top venture investment for the first half of 2012 was delivered by the VC arm of billionaire Randal Kirk to his big biotech venture Intrexon.

These days, it's good to have your own money to bank on when you're growing a big biotech company.

It's also extraordinarily rare.

The first half of the year delivered a long string of red flags on the venture side of the business. Startups were finding it harder than ever to gain new rounds as investing plunged in the second quarter of the year. And that same bottom line was reached by every group that crunches the numbers.

Over the last quarter biotech companies scraped together $697 million in 90 deals, a stinging 42% drop compared to the same period a year ago and the lowest level the National Venture Capital Association--which got its numbers from Thomson Reuters--has seen since the first quarter of 2003.

Which doesn't mean there isn't a silver lining. The buyout deals struck in recent months--Amylin and Human Genome Sciences, for example--show that Big Pharma is still finding many of its best new products in companies it can easily afford to buy. With AstraZeneca ($AZN) and others anxious to grow pipelines, willing to license what they won't buy, you can look for more deals in the future. And as long as such buyers are out there, new biotechs will be coming around to look for a deal.

The following 15 venture rounds qualified as the top investments of the first half, as tracked by Thomson Reuters and the National Venture Capital Association. At first glance, you may wonder where the figures come from. FierceBiotech runs the rounds as they're touted by the companies. The NVCA tracks actual dollars that are flowing to the company in a designated time period. So Tesaro ($TSRO), which announced a $101 million round of venture funding last year, got the bulk of that in a second tranche in the first half. Warp Drive Bio, which announced a $125 million Series A in January, actually landed $75 million last December.

 

Related

Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary

Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif